Monthly Archives: July 2016

Australian Researchers Identify the World’s Ugliest Color

The Australia government has sought to identify the single most unappealing color in an attempt to mandate tobacco distributors to use it on all product packaging to deter tobacco consumption.

Phoenix, United States – July 21, 2016 /PressCable/ —

The government of Australia had one chance to get it right. They sought to identify the single most unappealing color of all. They would then mandate that makers of tobacco products use that color on product packaging – as the background in photos of rotted teeth and tumor-laden tongues, and as the color of the type in on-pack health warnings. Their hope is that prominent use of the most disgusting color would help deter tobacco consumption.

The worldwide market research agency of GfK Bluemoon was hired to assist in the task. After surveying almost 1,000 respondents, the firm reached this conclusion: the most repulsive color is a bland mashup of dark brown and a putrid dark green, otherwise known in the color industry as the Pantone color shade 448 C and named Opaque Couché. Lime green, dark gray and mustard were runners-up.

Asked to discuss the transference of these learnings to interior design decisions, Mark Shook, owner of the leading online seller of kitchen furniture and accessories, Butcher Block Co., expressed no surprise. “Absolutely, these findings are applicable to the selection of colors for home interiors,” Shook confirmed. “Just as Opaque Couché conjures up unpleasant feelings when viewed on tobacco packaging, it certainly would have the same effect if featured on kitchen walls, countertops, cabinets or the base of a kitchen island or table. Especially in kitchens we want to be surrounded by colors that soothe and please us. Clearly, this brownish olive, would not fit the bill; nor would lime green, dark gray or mustard, for that matter.”

“Butcher Block Co.’s best-selling products tend to be neutral in appearance. They complement décor, rather than fight it,” Shook explained. “For example, for decades maple countertops have been the most popular, largely because of their very neutral coloration. After all, you will be staring at these colors day in and day out, and probably for many years. There certainly is such a thing as ‘color exhaustion,’ plus you’ll want a kitchen color scheme that will never go out of style.”

About Butcher Block Co. – Since 2007 BBC has been selling products for commercial and residential kitchens. The company specializes in butcher block countertops, standing blocks, and islands, tables and carts made of butcher block. The online store https://butcherblockco.com carries products made by eleven different manufacturers, including John Boos & Co. and Catskill Craftsmen.

For more information, please visit https://butcherblockco.com

Contact Info:
Name: Kathleen Grodsky
Organization: Butcher Block Co.
Address: 10448 N 21st Pl Phoenix, Arizona 85028
Phone: (877) 845-5597

Release ID: 124432

JULY 25, 2016 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Gerdau S.A. and Reminds Investors with Losses to Contact The Firm

LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Gerdau S.A. (“Gerdau” or the “Company”) (NYSE: GGB) concerning possible violations of federal securities laws between June 2, 2011 and May 15, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 25, 2016 lead plaintiff motion
deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that Gerdau issued false and misleading statements to investors and/or failed to disclose that: 1) the Company was engaged in a bribery scheme with Brazil’s Board of Tax Appeals; 2) Gerdau defrauded Brazilian tax authorities of about $429 million; 3) the Company’s CEO and other directors and employees engaged in bribery, money laundering, and peddling for influence; and 4) as a result, Gerdau’s public statements were materially false and misleading throughout the Class Period.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442677

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc And Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 21, 2016 / Lundin Law PC (the “Firm”) announces a class action lawsuit has been filed against Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP) concerning possible violations of federal securities laws between March 2, 2015 and May 6, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 25, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company failed to disclose that its arrangements with pharmacy benefit managers with respect to the migraine therapy Frova included questionable incentives intended to raise sales revenues, and as a result, Endo’s revenues and revenue projections relied in part on unsustainable arrangements. When this news was announced, shares of Endo dropped in value.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442676

APPROACHING DEADLINE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Ability Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Ability Inc. (“Ability” or the “Company”) (NASDAQ: ABIL). Investors who purchased or otherwise acquired shares between September 8, 2015 and April 29, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 25, 2016 lead plaintiff motion deadline.

If you purchased shares of Ability during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, during the Class Period, Ability issued false and misleading statements and/or failed to disclose that: the Company overstated its income by not accounting for commissions; the Company materially overstated its operating results by improperly recognizing revenue on multiple element sales transactions; Ability has material weaknesses in its internal controls; and as a result of the above, the Company’s financial statements for the years ending December 31, 2013 and 2014 were materially false and misleading, and not prepared in accordance with U.S. Generally Accepted Accounting Principles.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442675

SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August 1, 2016 lead plaintiff motion deadline.

If you purchased shares of Eagle during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made misrepresentations about the Food & Drug Administration (“FDA”) approval process for its new anticoagulant drug, KANGIO™. Specifically, on February 25, 2016, the Company’s CEO stated, regarding the pending New Drug Application (“NDA”) for KANGIO™, “We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.” On March 18, 2016 Eagle disclosed that the FDA did not approve the NDA because it required more information about the substances used in KANGIO™. When the news was revealed, shares dropped in value, causing investors harm.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442674

Bank of Napa Reports Strong Earnings Growth

NAPA, CA / ACCESSWIRE / July 21, 2016 / Bank of Napa, N.A. (OTCQB: BNNP) announced its financial results for the six-month period ending June 30, 2016, where the Bank earned $810,000 versus $601,000 in the same period last year, an increase of $209,000 or 34.8%. Net income in the second quarter of 2016 was $407,000, an increase of over $82,000 or 25.2% over that which was earned in the same period last year.

Total deposits at June 30, 2016 were $204.3 million, representing an increase from the balance outstanding at June 30, 2015 of $32.7 million. Gross Loan totals at June 30, 2016 increased to $128.3 million, up by $11.9 million from last year. Bank of Napa’s total assets reached $231.6 million at June 30, 2016, representing a $35.3 million or 18.0% increase over the same period last year.

At June 30, 2016, the Bank had equity capital of $25.8 million, and all capital ratios were in excess of the regulatory definition for “well capitalized” distinction.

Bank of Napa, N.A. offers a complete range of loan and deposit products, and services to businesses and consumers in the Napa Valley. It operates two full service offices: at the corner of Redwood Road and Solano Avenue at 2007 Redwood Road, Suite 101; and at Second and Seminary Streets at 1715 Second Street, in Napa CA. Bank of Napa is a member of the FDIC. Its common stock is traded on the OTCQB under the symbol BNNP and the Bank can be found on the web at www.thebankofnapa.com. Contact Information: Tom LeMasters, President & CEO, 707-257-7777.

Information contained herein may contain certain forward-looking statements that are based on management’s current expectations regarding economic, legislative, and regulatory issues that may impact the Bank’s earnings in future periods. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include the words “believe,” “expect,” “intend,” “estimate” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could” or “may.” Factors that could cause future results to vary materially from current management expectations include, but are not limited to, general economic conditions, changes in interest rates, deposit flows, real estate values, and competition; changes in accounting principles, policies or guidelines; changes in legislation or regulation; and other economic, competitive, governmental, regulatory and technological factors affecting the Bank’s operations, pricing, products and services. The Bank undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

SOURCE: Bank of Napa, N.A.

ReleaseID: 442544

INVESTOR ALERT – Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action against Juno Therapeutics, Inc. (JUNO) & Lead Plaintiff Deadline: September 12, 2016

NEW YORK, NY / ACCESSWIRE / July 21, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors
that a securities class action has been filed in the United States District Court Western District of Washington on behalf of those who purchased shares of Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ: JUNO) and certain of its officers, during the period between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.

Juno is a biopharmaceutical company founded in 2013 that is developing cell-based cancer immunotherapies. JCAR015, its leading product candidate, is currently in clinical trials.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Juno’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or partial disclosures regarding JCAR015’s safety and made public misrepresentations or failed to disclose material facts of the death of patients in its Phase 2 clinical trial.

In May 2016, a patient in the Phase 2 trial of JCAR015 died of a cerebral edema, a form of neurotoxicity. Two additional patients in the ROCKET trial died of cerebral edemas by early July, causing the FDA to issue a clinical hold which forced Defendants to reveal the truth on July 7, 2016, post-market. Following this news, Juno’s stock dropped $13.01 per share, or 31.87%, to close at $27.81 on July 8, 2016.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!juno/c3onh or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Juno, you have until September 12,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442532

INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action against Insmed Incorporated (INSM) and Lead Plaintiff Deadline: September 13, 2016

NEW YORK, NY / ACCESSWIRE / July 21, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court District of New Jersey on behalf of those who purchased shares of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM) and certain of its officers, during the period between March 18, 2013 and June 8, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.

Insmed, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapies for patients with serious lung diseases. ARIKAYCE™ (Liposomal Amikacin for Inhalation, or LAI), Insmed’s lead product candidate, is an investigational drug comprising the antibiotic amikacin in the Company’s proprietary liposomal technology formulation. ARIKAYCE is in late-stage clinical development for treatment of serious lung infections such as those caused by nontuberculous mycobacteria (NTM), through delivery of antibiotic directly to the site of the lung infection.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting Insmed’s European marketing authorization application (“MAA”) for Arikayce was not likely to be approved by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease; (2) Arikayce’s endorsement by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were therefore not as likely than Insmed had led its investors to believe; and (3) consequentially, Insmed’s public statements were materially false and misleading at all relevant times.

On June 8, 2016, post-market, Insmed revealed that it had removed Arikayce’s treatment of NTM lung disease MAA from the EMA. Insmed said, “During the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting, the CHMP indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval. Insmed intends to resubmit its MAA when clinical data from its ongoing global phase 3 study are available.” Following this news, Insmed stock dropped $0.99 per share, or 8.24% to close at $11.02 on June 9, 2016.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!insm/iz8zm or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Insmed, you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442533

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Joy Global, Inc. to Komatsu Ltd. is Fair to Shareholders – JOY

NEW YORK, NY / ACCESSWIRE / July 21, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Joy Global, Inc. (“Joy Global”) (NYSE: JOY) stock prior to July 21, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Joy Global to Komatsu Ltd. for $28.30 in cash per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/joy-global-joy or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 442673

Thermalabs Supremasea Brand Packaging Its Latest Products

Thermalabs Supremasea brand is almost ready to introduce its new products to the market.

New York, United States – July 21, 2016 /MarketersMedia/ —

Thermalabs Supremasea sub-brand has said that it’s in the process of packaging at least two of its latest products. This is a positive development especially considered that Supremasea has been working on exclusive new formulations over the last couple of months. Supremasea brand manager, Kristina Meyers, has said that more top-quality products will be available through Amazon.com and major online marketplaces any time from now. The company is also shipping units of these new products to local cosmetics outlets in Europe, the US and select other parts of the world.

Supremasea is a Thermalabs sub-brand that was introduced in 2015. Headed by Ann Spencer and a team of specially trained employees, Supremasea oversee the production, distribution, and marketing of Thermalabs private collection of top-notch skincare products based on Dead Sea salts and minerals. Scientists have said that the Dead Sea is home to at least 12 salts that aren’t available anywhere else in the world. By making use of these special salts, and combining them with other ingredients whose benefits for the skin are well known, Thermalabs is looking to furnish the market with a new range of highly effective products.

Based on information distributed by Ms. Meyers, the new products will be highly beneficial for the skin. They will feature an innovative formulation that combines mineral salts with other organic ingredients to deliver multiple benefits for the skin. The products will be available through Amazon.com as well as through the company’s official website.

Already, Supremasea’s first launch, Tan Enhancer, is performing well in the market. Tan Enhancer was created from a combination of Dead Sea salts and conventional skincare ingredients such as Shea Butter. The product comes across the board as a luxury lotion that leads to that perfect glow that most people yearn for after a tan. It’s fortified with Vitamin E to protect the skin from free radicals and environmental pollutants. Tan Enhancer also moisturizes the skin and keeps it supple all day long.

Jeniffer, an Amazon user who bought and rated Tan Enhancer product 5-star, reviewed, “These worked very well gave me a nice even streak free light tan. I used three towels on each application and applied twice. I am very happy with the results just be sure to wear gloves and exfoliate your knees and elbows well. I took before and after pics. I think this is as dark as l will go so it looks natural and in the hot sunny months l will go darker. Worked very good on my face. I love my tan complexion. Better than any product I’ve ever picked up at a pharmacy. I will definitely be buying again.”

For more information, please visit http://www.thermalabs.com/home

Contact Info:
Name: James Crothers
Organization: Thermalabs

Video URL: https://www.youtube.com/watch?v=vYHl45Cymuw

Source: http://marketersmedia.com/thermalabs-supremasea-brand-packaging-its-latest-products/123969

Release ID: 123969